DRUGS AND MEDICINES: BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS, DRUGS AND MEDICINES FOR CARDIOVASCULAR SYSTEM, RESPIRATORY SYSTEM AND INSULIN AND ANALOGUES (P.R. NO. 2026-10-1824)

DRUGS AND MEDICINES: BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS, DRUGS AND MEDICINES FOR CARDIOVASCULAR SYSTEM, RESPIRATORY SYSTEM AND INSULIN AND ANALOGUES (P.R. NO. 2026-10-1824) Item Description ABC Unit Quantity 1 AMIODARONE HYDROCHLORIDE 200MG TABLET 9,900.00 TABLET 200.00 2 AMLODIPINE BESILATE OR CAMSYLATE 5MG TABLET 73,500.00 TABLET 21,000.00 3 ASPIRIN 80MG TABLET 31,680.00 TABLET 11,000.00 4 ATORVASTATIN CALCIUM 20MG TABLET 4,980.00 TABLET 1,000.00 5 BIPHASIC ISOPHANE 70%+30% HUMAN INSULIN SOLUBLE (RECOMBINANT DNA) IN 100IU/ML SUSPENSION FOR INJECTION, 10ML VIAL (SC) 287,500.00 VIAL 500.00 6 CILOSTAZOL 50MG TABLET 1,210.00 TABLET 100.00 7 CLOPIDOGREL 75MG TABLET 60,000.00 TABLET 6,000.00 8 ENOXAPARIN SODIUM 100MG/ML, 0.6ML PRE-FILLED SYRINGE (SC) 250,000.00 PFS 500.00 9 ESMOLOL HYDROCHLORIDE 10MG/ML, 10ML VIAL (IV) 9,880.00 VIAL 10.00 10 FLUTICASONE PROPIONATE 250MCG+25MCG SALMETEROL XINAFOATE, 120 ACTUATIONS MDI 25,997.50 PIECE 50.00 11 HEPARIN SODIUM (UNFRACTIONATED,BOVINE ORIGIN) 5000 IU/ML, 5ML VIAL (IV, SC) 214,200.00 VIAL 900.00 12 HYDROCHLOROTHIAZIDE 25MG TABLET 550.00 TABLET 100.00 13 IPRATROPIUM BROMIDE 250MCG/ML, 2ML (UNIT DOSE) (RESPIRATORY SOLUTION FOR NEBULIZATION) 900,000.00 PIECE 6,000.00 14 ISOSORBIDE DINITRATE 5MG SUBLINGUAL TABLET 14,400.00 TABLET 800.00 15 LOSARTAN POTASSIUM 50MG TABLET 160,000.00 TABLET 32,000.00 16 NIFEDIPINE 30MG MR TABLET 9,800.00 TABLET 200.00 17 NIMODIPINE 30MG TABLET 35,776.00 TABLET 1,300.00 18 ROSUVASTATIN CALCIUM 10MG TABLET 4,365.00 TABLET 300.00 19 ROSUVASTATIN CALCIUM 20MG TABLET 14,000.00 TABLET 500.00 20 SACUBITRIL 24.3MG + VALSARTAN 25.7MG TABLET 52,698.80 TABLET 812.00 21 TELMISARTAN 40MG TABLET 16,500.00 TABLET 1,000.00 22 TELMISARTAN 80MG TABLET 6,980.00 TABLET 200.00 23 VALSARTAN 160MG TABLET OR FILM COATED TABLET 1,248.00 TABLET 100.00 TERMS OF REFERENCE 4TH QUARTER PUBLIC BIDDING TO ENSURE AVAILABILITY AND ADMINISTRATION OF BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS, DRUGS & MEDICINES FOR CARDIOVASCULAR SYSTEM, RESPIRATORY SYSTEM, & INSULIN AND ANALOGUES P.R. # 2026-10-1824 The drug & medicine should have at least 18 months of expiration from the delivery date. The winning bidder however may provide a guarantee letter to pull-out and replace near expiry items 3 months prior to expiration date once the expiration date is lower than 18 months. Acceptance of near expiry medicines will depend on the need of the Pharmacy Section and the approval of Materials Management Section Head. Pharmacy Section will have the option to retain 3 months projection of near expiry medicines if no longer expiry is available. In the event that supplier fails to pull-out expired items 3 months prior to date of expiry, it will be automatically considered as pulled-out and will be reflected as deduction from the supplier’s account. All suppliers to attach return policy even for more than 18-month expiry. Suppliers must provide FDA License to Operate (LTO) as Drug Wholesaler, and Certificate of Sub – distributorship from the manufacturer or distributor if the supplier’s company name does not appear in the CPR. Suppliers must provide FDA Certificate of Product Registration (CPR) Suppliers must provide FDA Certificate of Good Manufacturing Practice (CGMP) All labels/packaging of all drugs & medicines must have a readable Name of Drug, Lot Number, Manufacturing and Expiration Date. Pre-bid Conference Date Time Venue 12/11/2026 9:00 AM at the REODICA HALL which can also be viewed via GOOGLE MEET with the following details: Join with Google Meet: Link: https://meet.google.com/emq-rtig-ihe Other Information Kindly see attached Public Bidding Documents Created by Ma. Christina C. Pabicon Date Created 29/10/2026 The PhilGEPS team is not responsible for any typographical errors or misinformation presented in the system. PhilGEPS only displays information provided for by its clients, and any queries regarding the postings should be directed to the contact person/s of the concerned party. ©&nbsp2004-2026 DBM Procurement Service. All rights reserved. Help | Contact Us | Sitemap